Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Liraglutide for Weight Management
NCT04074161Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by Novo Nordisk. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04074161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074161.